Pharmacokinetic Interaction Between Favipiravir and Amlodipine in Hypertensive Local Rabbits (Oryctolagus cuniculus)

In the treatment of COVID-19, antiviral medication Favipiravir has proven to be quite successful. Its metabolism is mediated by enzymes aldehyde oxidase (AO) and xanthine (XO). This research investigated potential drug-drug interaction betweenfavipiravir amlodipine in hypertensive rabbits. Twenty local adult male rabbits (aged between 10 12 months weighing 2 2.5 kg) were induced with hypertension 20 mg/kg BW desoxycorticosterone acetate subcutaneously for three weeks then divided randomly into two groups ten. The first group received a single oral dose 40 favipiravir, while second 5 orally 14 consecutive days inhibit AO before receiving favipiravir. Blood samples collected from marginal ear vein at 15, 30, 45 min, 1, 2, 4, 8, 12, 24, 48, 36, 72 h. High-performance liquid chromatography (HPLC) was used determine concentration favipiravir plasma. results showed that co-administration prolonged time taken (Tmax) reach maximum plasma (Cmax) decreased its elimination half-life, increasing area under curve (AUC). Amlodipine also reducing clearance per unit (Cl/f). Additionally, potentiated effect on absorption, distribution, metabolism, excretion conclusion, concomitant use other drugs affect enzyme activity may alter pharmacokinetic profile drug. Therefore, adjusting administered patients recommended.